Inactive Instrument
Norda ASA Share Price Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 51Cr 5.45Cr 4.75Cr 4.49Cr 4.08Cr 7.62Cr 521.83Cr 7.66Cr 53Cr 21Cr 265.2Cr 20Cr 20Cr 848.97Cr | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 26Cr 2.81Cr 2.44Cr 2.31Cr 2.1Cr 3.93Cr 268.82Cr 3.95Cr 28Cr 11Cr 136.61Cr 11Cr 10Cr 437.33Cr | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 09/04 | Exercise of Warrants by primary insiders | AQ |
| 10/25/10 | Mandatory Notification of Trade | AQ |
| 04/25/04 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/25/27 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/25/03 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 4.72Cr | ||
| +1.23% | +1.87% | -0.15% | +9.57% | 4.59TCr | ||
| +0.23% | +4.72% | +44.32% | +27.27% | 4.42TCr | ||
| +0.52% | -3.15% | +349.53% | +520.09% | 4.2TCr | ||
| +1.55% | +3.41% | +6.40% | +76.45% | 3.96TCr | ||
| +1.75% | -0.28% | +12.42% | +41.11% | 3.11TCr | ||
| -0.20% | +5.49% | +23.57% | +119.72% | 1.72TCr | ||
| -3.49% | -8.49% | - | - | 1.63TCr | ||
| +2.92% | +8.40% | +22.46% | +38.87% | 1.5TCr | ||
| -2.45% | +2.41% | -3.16% | -35.16% | 1.34TCr | ||
| Average | +0.54% | +0.77% | +56.93% | +99.74% | 2.94TCr | |
| Weighted average by Cap. | +0.59% | +0.33% | +72.35% | +120.61% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 8.69Cr 92.29L 80.39L 76.08L 69.12L 1.29Cr 88Cr 1.3Cr 9.06Cr 3.5Cr 45Cr 3.47Cr 3.39Cr 143.8Cr | 37Cr 3.95Cr 3.44Cr 3.25Cr 2.96Cr 5.52Cr 378.13Cr 5.55Cr 39Cr 15Cr 192.17Cr 15Cr 15Cr 615.18Cr |
| Net income | 3.12Cr 33.1L 28.83L 27.28L 24.79L 46.31L 32Cr 46.54L 3.25Cr 1.26Cr 16Cr 1.24Cr 1.22Cr 52Cr | 13Cr 1.34Cr 1.16Cr 1.1Cr 1Cr 1.87Cr 128.07Cr 1.88Cr 13Cr 5.08Cr 65Cr 5.02Cr 4.91Cr 208.36Cr |
| Net Debt | -31Cr -3.3Cr -2.88Cr -2.72Cr -2.48Cr -4.62Cr -316.5Cr -4.65Cr -32Cr -13Cr -160.85Cr -12Cr -12Cr -514.91Cr | -25Cr -2.64Cr -2.3Cr -2.18Cr -1.98Cr -3.7Cr -253.02Cr -3.71Cr -26Cr -10Cr -128.59Cr -9.92Cr -9.7Cr -411.64Cr |
Employees
-
















